ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.07
-0.51 (-2.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close21.58
Open21.69
Bid20.70 x 3000
Ask21.04 x 900
Day's Range20.70 - 21.69
52 Week Range12.77 - 32.99
Volume2,635,110
Avg. Volume2,380,450
Market Cap3.026B
Beta (3Y Monthly)3.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
    Zacks3 days ago

    Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

    Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    # ACADIA Pharmaceuticals Inc ### NASDAQ/NGS:ACAD View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderately high for ACAD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.92 billion over the last one-month into ETFs that hold ACAD are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December
    Motley Fool12 days ago

    Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December

    The pharma company was an easy target for Mr. Market during last month's sell-off, but it appears well positioned for a rebound in 2019.

  • Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
    Market Realist24 days ago

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.

  • Spectrum Pharmaceuticals: Financial Overview in December
    Market Realist24 days ago

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.

  • Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
    Insider Monkeylast month

    Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?

    “Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]

  • Simply Wall St.last month

    Why ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Your Next Investment

    I've been keeping an eye on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
    Market Realist2 months ago

    Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

    On November 28, Acadia Pharmaceuticals (ACAD) stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27. On November 27, Acadia Pharmaceuticals announced a price of $17.00 per share for an underwritten public offering of 16,176,471 shares of its common stock. Acadia Pharmaceuticals’ net revenue in the first nine months of the year amounted to $164.2 million compared to $81.3 million in the same period last year.

  • Here's Why Acadia Pharmaceuticals Is Soaring
    Motley Fool2 months ago

    Here's Why Acadia Pharmaceuticals Is Soaring

    Shares rebound after the company announces the pricing details of its common stock offering.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Benzinga2 months ago

    The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...

  • A Look at Amarin Corporation’s Stock Performance Year-to-Date
    Market Realist2 months ago

    A Look at Amarin Corporation’s Stock Performance Year-to-Date

    Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ACAD earnings conference call or presentation 6-Nov-18 10:00pm GMT

    Q3 2018 ACADIA Pharmaceuticals Inc Earnings Call

  • Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
    Simply Wall St.2 months ago

    Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

    ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Read More...

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

    Acadia (ACAD) delivered earnings and revenue surprises of 13.79% and 0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Acadia: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of 50 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a ...

  • How Wall Street Analysts View Exelixis
    Market Realist2 months ago

    How Wall Street Analysts View Exelixis

    Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
    Zacks3 months ago

    Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

    Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 29) Gamida Cell Ltd (NASDAQ: GMDA ) NeoGenomics, Inc. (NASDAQ: ...

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Investopedia3 months ago

    3 Biotech Stocks Poised to Rise by 15% or More

    The SPDR Biotech ETF ( XBI) had been up 18% for 2018 at the start of September.  Since then the Biotech ETF has given up nearly all of its gains and is now up less than 1% on the year. But not all biotechs have been poor performers during this time, and some may be poised to gain 15% or more in the final few weeks of 2018. The stock reached an intraday high of $23.50 on October 18, and should the stock be able to rise above technical resistance at $24, it could be on its way to $27.20. Should the stock rise above technical resistance at $45.25, the shares could increase to roughly $50.